What is Endomag?
Headquartered in Cambridge, UK, Endomag specializes in the development of advanced medical devices designed to address complex healthcare challenges, particularly in cancer staging. The company's core technology, which originated from research at University College London and the University of Houston, utilizes ultrasensitive magnetic sensing to track nanoscale materials within the human body. Its flagship product, the SentiMag probe, represents a significant shift in surgical precision, offering clinicians a non-radioactive alternative for sentinel lymph node biopsy. By bridging the gap between academic research and clinical application, Endomag has established itself as a leader in the medical technology sector, focusing on scalable, patent-protected solutions that improve patient outcomes while streamlining hospital workflows.
How much funding has Endomag raised?
Endomag has raised a total of $38.3M across 5 funding rounds:
Series A
$2M
Series B
$3.2M
Private Equity
$3.1M
Series C
$10M
Series D
$20M
Series A (2011): $2M with participation from Bloomsbury Bioseed Fund and Sussex Place Ventures
Series B (2013): $3.2M led by New Wave Ventures and Sussex Place Ventures
Private Equity (2014): $3.1M supported by UCL Business and New Wave Ventures
Series C (2018): $10M featuring Molten
Series D (2020): $20M backed by Sussex Place Ventures Ltd and Draper Esprit plc
Key Investors in Endomag
New Wave Ventures
A UK-based private investment firm established in 2010 that prioritizes high-growth potential and provides both essential capital and strategic guidance to its portfolio companies.
Sussex Place Ventures
An early-stage venture capital firm associated with the London Business School, specializing in supporting entrepreneurs developing patent-protectable deep technology and enterprise software.
UCL Business
The commercialization arm of University College London, dedicated to bringing world-leading academic innovations and pioneering research to the global market.
What's next for Endomag?
With the recent infusion of capital, Endomag is well-positioned to scale its commercial operations and deepen its penetration into international markets. The company's strategic roadmap focuses on the continued adoption of its SentiMag and Sienna+ platforms, which are increasingly becoming the standard of care in surgical oncology. As the firm transitions from a development-focused entity to a global commercial powerhouse, management is expected to prioritize clinical evidence generation and the expansion of its diagnostic portfolio. This phase of growth will likely involve strengthening distribution partnerships and navigating regulatory landscapes to ensure the widespread availability of its magnetic sensing solutions, ultimately reinforcing its competitive moat in the high-growth medical device market.
See full Endomag company page
